Author:
Brennan Barbara J.,Poirier Agnès,Moreira Sebastian,Morcos Peter N.,Goelzer Petra,Portmann Renée,Asthappan Jiney,Funk Christoph,Smith Patrick F.
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology
Reference36 articles.
1. Marcellin P, Cooper C, Balart L, Larrey D, Box T, Yoshida E, et al. Randomized controlled trial of danoprevir plus peginterferon alfa-2a and ribavirin in treatment-naive patients with hepatitis C virus genotype 1 infection. Gastroenterology. 2013;145:790–800.
2. Everson G, Cooper C, Hezode C, Shiffman ML, Yoshida E, Beltran-Jaramillo T, et al. DAUPHINE: a randomized phase II study of danoprevir/ritonavir plus peginterferon alpha-2a/ribavirin in HCV genotypes 1 or 4. Liver Int. 2014. doi: 10.1111/liv.12471 .
3. Gane EJ, Roberts SK, Stedman CA, Angus PW, Ritchie B, Elston R, et al. Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet. 2010;376:1467–75.
4. Jensen DM, Brunda M, Elston R, Gane EJ, George J, Glavini K, et al. Interferon-free regimen containing setrobuvir (STV) in combination with ritonavir-boosted danoprevir (DNVr) and ribavirin (R) with or without mericitabine (MCB) in HCV genotype (G)1 treatment-naive patients: SVR4 results from the ANNAPURNA study (abstract 1098). Hepatology. 2013;58(Suppl):741A.
5. Feld JJ, Jacobson IM, Jensen DM, Foster GR, Pol S, Tam E, et al. Randomised study of danoprevir/ritonavir-based therapy for HCV genotype 1 patients with prior partial or null responses to peginterferon/ribavirin. J Hepatol. 2014. doi: 10.1016/j.jhep.2014.09.013 .
Cited by
12 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献